BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook
BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...
Peering Into BioNTech's Recent Short Interest
According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...
Moderna stock rises following RFK Jr's comments
Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) climbed 5.4% mid-day Tuesday as remarks by RFK Jr, who clarified his stance as not being anti-vaccine or anti-industry, appeared to bolster investor ...
RFK Jr. reportedly softens his antivaccine stance ahead of confirmation hearing
Ahead of his confirmation hearing this week, Robert F. Kennedy Jr., President Donald Trump’s nominee for HHS Secretary, has ...
Morningstar2d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioNTech SE (BNTX) Receives a Hold from J.P. Morgan
In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...
Morgan Stanley Sticks to Their Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
BioNTech SE (NASDAQ:BNTX) Position Increased by Atomi Financial Group Inc.
Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...
BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...
Evotec SE: Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaborati ...